For laboratory facilities requiring rapid delivery of high-purity growth hormone-releasing hormone (GHRH) analogs, PX1 Research provides CJC-1295 No DAC with fast shipping and comprehensive analytical verification. Synthesized in US-based, GMP-compliant facilities, every lot undergoes rigorous HPLC, mass spectrometry, and endotoxin analysis to ensure maximum experimental reproducibility across tissue repair and cellular signaling research.
For laboratory facilities requiring rapid delivery of high-purity growth hormone-releasing hormone (GHRH) analogs, PX1 Research provides CJC-1295 No DAC with fast shipping and comprehensive analytical verification. Synthesized in US-based, GMP-compliant facilities, every lot undergoes rigorous HPLC, mass spectrometry, and endotoxin analysis to ensure maximum experimental reproducibility across tissue repair and cellular signaling research.
For research facilities requiring rapid acquisition of high-purity CJC-1295 No DAC (Modified GRF 1-29), PX1 Research provides USA-manufactured, HPLC/MS-verified peptides with same-day shipping on orders placed Monday through Friday before 1:00 PM PST from fulfillment hubs in California and Arizona. Each lot includes a comprehensive third-party Certificate of Analysis (COA) confirming purity and endotoxin levels.
Timely delivery is critical for maintaining experimental continuity in high-throughput laboratories. Delays in reagent procurement can compromise research schedules, degrade biological assays, or stall longitudinal animal studies. PX1 Research mitigates supply chain friction by maintaining robust domestic inventory levels of lyophilized CJC-1295 No DAC and utilizing expedited distribution networks. Laboratory managers receive instant tracking details, batch-specific analytical documentation, and climate-controlled packaging designed to preserve peptide integrity during transit.
By sourcing directly from domestic manufacturing operations, research teams eliminate international customs delays, unpredictable tariff holds, and unknown storage conditions common to overseas vendors. Whether conducting acute cellular response studies or extended animal models, researchers can rely on predictable delivery timelines and uncompromised reagent quality.
CJC-1295 No DAC, structurally identified as Modified GRF (1-29), is a synthetic 29-amino-acid peptide derived from the functional N-terminal region of endogenous Growth Hormone-Releasing Hormone (GHRH). In naturally occurring GHRH(1-44), biological activity is localized within the first 29 amino acids, but native peptide chains suffer rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). CJC-1295 No DAC incorporates specific amino acid substitutions—specifically D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27—to confer resistance against enzymatic cleavage without altering receptor binding affinity.
As a potent GHRH analog, CJC-1295 No DAC binds specifically to the growth hormone-releasing hormone receptor (GHRH-R) expressed on anterior pituitary somatotrophs. Receptor activation stimulates the G-protein coupled receptor (GPCR) pathway, triggering intracellular cyclic adenosine monophosphate (cAMP) accumulation and protein kinase A (PKA) signaling cascades. This pathway prompts the synthesis and exocytosis of endogenous growth hormone (GH) in a physiologic, pulsatile manner.
Because CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) maleimide moiety, it does not form covalent bonds with circulating serum albumin. Consequently, its plasma half-life is measured in minutes to hours rather than days, making it ideal for laboratory protocols that require tight control over transient GH spikes without causing constant, baseline receptor saturation.
In preclinical rodent models, CJC-1295 No DAC has been studied extensively as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. In vivo investigations demonstrate that administration of Modified GRF (1-29) induces a physiological pulse of growth hormone, which subsequently stimulates hepatic secretion of Insulin-like Growth Factor 1 (IGF-1). This dual elevation of GH and IGF-1 plays a central role in regulating protein synthesis, extracellular matrix deposition, and cellular regeneration in preclinical tissue injury models.
In vitro data indicate that elevated downstream IGF-1 signaling activates the PI3K/Akt and MAPK/ERK pathways within skeletal muscle myoblasts, dermal fibroblasts, and articular chondrocytes. These intracellular cascades promote cell proliferation, suppress apoptotic cascades, and upregulate collagen gene expression. Researchers investigating tendon healing, skeletal muscle recovery, and focal cartilage defects frequently utilize GHRH analogs to explore how localized paracrine IGF-1 dynamics accelerate structural remodeling.
Furthermore, animal models evaluating metabolic regulation show that GHRH receptor agonism mediated by Modified GRF (1-29) alters substrate utilization. Preclinical evidence suggests enhanced lipolysis in adipose tissue alongside augmented amino acid transport in muscular tissue, providing valuable insights into metabolic rate modulation, insulin sensitivity, and lean tissue preservation during catabolic states.
Understanding the distinctions among growth hormone secretagogues is vital when selecting reagents for specific experimental designs. CJC-1295 No DAC belongs to the GHRH analog class, but its structural and pharmacokinetic traits set it apart from other compounds in the broader growth hormone secretagogues spectrum.
When evaluated against CJC-1295 with DAC, the primary variable is serum persistence. The addition of the DAC reactive group enables covalent binding to endogenous albumin, extending plasma half-life to several days and producing sustained, non-pulsatile elevations in GH and IGF-1. In contrast, CJC-1295 No DAC exhibits rapid clearance, permitting researchers to mimic endogenous circadian secretory patterns. Compared to first-generation truncated analogs like Sermorelin, CJC-1295 No DAC features targeted amino acid substitutions that grant superior resistance to DPP-IV enzymatic degradation, resulting in enhanced biostability in aqueous media.
Additionally, research protocols frequently contrast GHRH analogs with ghrelin receptor agonists such as Ipamorelin. While CJC-1295 No DAC acts via the GHRH receptor, ghrelin mimetics target the growth hormone secretagogue receptor (GHSR-1a). Co-incubation or combined administration in animal models often demonstrates synergistic GH release, as activation of both receptor pathways yields greater somatotroph secretion than stimulating either pathway independently. For comprehensive catalog options, explore our complete catalog of research peptides.
PX1 Research enforces strict quality assurance protocols to guarantee that every vial of CJC-1295 No DAC meets exacting analytical standards. Chemical purity is verified through standard Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). RP-HPLC separates the target peptide from synthesis byproducts, truncated sequences, and residual protecting groups. PX1 Research mandates a minimum purity threshold of 98.0% for all catalog lots.
Identity verification is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF). Mass spectrometry measures the exact molecular weight of the peptide, verifying that the amino acid sequence matches the theoretical mass of Modified GRF (1-29) (C152H252N44O42, theoretical molecular weight: 3367.9 g/mol) without unwanted adducts or translational errors.
Because biological assays—particularly cell culture and animal models—are sensitive to bacterial contaminants, endotoxin testing is mandatory. PX1 Research screens every batch using quantitative Limulus Amebocyte Lysate (LAL) assays to confirm endotoxin levels remain strictly below <0.05 EU/mg. Detailed documentation, including raw chromatograms and mass spectra, is accessible via our PX1 Research library and linked to each lot.
All CJC-1295 No DAC supplied by PX1 Research is synthesized in state-of-the-art facilities located within the United States adhering to Good Manufacturing Practice (GMP) guidelines and ISO 17025 laboratory standards. Domestic production ensures strict oversight of reagent quality, environmental controls, and batch traceability from raw amino acid coupling to final lyophilization.
Our logistics infrastructure utilizes dual fulfillment nodes in California and Arizona. Distributing inventory across both West Coast and Southwestern hubs allows PX1 Research to execute rapid transit times across North America. Orders processed before 1:00 PM PST Monday through Friday are packed and dispatched the same day using expedited carrier services.
Lyophilized peptides are packaged in temperature-resilient, padded containers designed to withstand ambient environmental fluctuations during transport. For institutional researchers purchasing in high volumes, PX1 Research offers streamlined procurement via our wholesale lab accounts program, guaranteeing supply chain priority and lot reservation for multi-phase scientific projects.
Correct reconstitution protocols are essential for maintaining peptide stability and preventing physical aggregation or chemical degradation. CJC-1295 No DAC is supplied as a sterile, lyophilized white powder in sealed glass vials. Reconstitution should always be conducted inside a certified laminar flow hood utilizing aseptic technique.
Researchers typically utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-dose laboratory assays or sterile 0.9% Sodium Chloride Injection for acute in vitro applications sensitive to preservative agents. To reconstitute, slowly inject the diluent down the glass interior wall of the vial rather than directing the liquid stream directly onto the lyophilized cake. Allow the liquid to gently hydrate the powder, rotating the vial gently by hand. Vigorous shaking or mechanical vortexing must be avoided, as high shear forces can induce peptide denaturing or aggregation.
For specialized cell culture models where salt concentration must be controlled, researchers can consult technical guides available in our GHRH analogs overview section. Always calculate concentration based on total solvent volume to ensure precise micro-molar dosing in downstream bioassays.
Lyophilized CJC-1295 No DAC exhibits superior long-term stability when stored under controlled thermal conditions. Unopened vials should be stored in a commercial freezer at -20°C or -80°C, protected from light exposure. Under these conditions, the lyophilized peptide remains stable for up to 24 months without significant hydrolysis or oxidation.
Once reconstituted into aqueous solution, the peptide's chemical stability decreases. Reconstituted CJC-1295 No DAC solutions should be kept refrigerated at 2°C to 8°C and utilized within 14 to 30 days when formulated with bacteriostatic diluents. If experiments require extended storage of liquid aliquots, the solution should be divided into single-use working volumes and immediately frozen at -80°C to minimize degradation.
Repeated freeze-thaw cycles must be strictly avoided. Freeze-thaw stress leads to ice crystal formation that cleaves peptide backbones and promotes covalent dimerization. Vials should be brought to room temperature prior to opening or reconstitution to prevent condensation accumulation inside the container.
Selecting a reliable supplier for research-grade reagents requires systematic verification of analytical transparency and quality control infrastructure. Research organizations evaluating vendors should demand comprehensive proof of purity and consistency prior to committing resources.
A rigorous supplier verification checklist includes: 1) Independent third-party COAs generated by accredited ISO 17025 laboratories for every individual lot; 2) Full RP-HPLC chromatograms displaying baseline resolution and integration metrics; 3) High-resolution ESI-MS mass spectrum data validating molecular identity; 4) LAL endotoxin quantification metrics ensuring compliance with biological cell culture parameters; and 5) Domestic US manufacturing with traceable lot numbers.
PX1 Research satisfies each of these criteria, offering complete operational transparency. Institutional buyers can review our technical resources on endotoxin testing standards and evaluate raw analytical spectra before purchasing to ensure complete confidence in their experimental inputs.
What is the structural difference between CJC-1295 No DAC and CJC-1295 With DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) maleimide moiety. Without DAC, the peptide does not bind covalently to circulating albumin, resulting in a short half-life measured in hours rather than days. This allows researchers to induce pulsatile GH release rather than continuous elevation.
How fast does PX1 Research ship CJC-1295 No DAC orders?
PX1 Research dispatches CJC-1295 No DAC orders placed Monday through Friday before 1:00 PM PST on the same day. Expedited shipping originates from our domestic fulfillment centers in California and Arizona.
What purity verification is provided with CJC-1295 No DAC?
Every lot of CJC-1295 No DAC undergoes third-party testing via RP-HPLC and ESI Mass Spectrometry to guarantee chemical purity exceeding 98.0%. A lot-specific Certificate of Analysis (COA) is provided with full analytical data.
What endotoxin limits are established for PX1 Research peptides?
All research peptides from PX1 Research undergo Limulus Amebocyte Lysate (LAL) testing to confirm that endotoxin levels remain below <0.05 EU/mg, ensuring suitability for sensitive in vitro and animal models.
How should lyophilized CJC-1295 No DAC be stored upon receipt?
Unopened lyophilized vials should be stored at -20°C or -80°C in a dry, dark environment. Under proper freeze storage, the lyophilized peptide remains stable for up to 24 months.
What diluent should be used for reconstituting CJC-1295 No DAC in lab settings?
Laboratory protocols typically employ sterile Bacteriostatic Water (0.9% benzyl alcohol) for extended reconstituted stability, or sterile 0.9% Sodium Chloride for acute assays where preservatives could interfere with cellular pathways.
Can CJC-1295 No DAC be co-administered with GHRP peptides in preclinical models?
Yes, in laboratory studies, GHRH analogs like CJC-1295 No DAC are frequently co-incubated or combined in animal models with GHRP compounds such as Ipamorelin or GHRP-6 to study receptor synergy and enhanced GH secretion.
Is CJC-1295 No DAC intended for human therapeutic use?
No. CJC-1295 No DAC supplied by PX1 Research is strictly designated for laboratory research use only by qualified scientific professionals. It is not for human or animal clinical use, therapeutic application, or personal administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.